Meeting
2012 ASCO Annual Meeting
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.
Authors
Gregory Russell Pond
McMaster University, Hamilton, ON, Canada
Gregory Russell Pond , Guru Sonpavde , Toni K. Choueiri , Angela Q. Qu , David J. Vaughn , Ronan Fougeray , Guenter Niegisch , Peter Albers , Yu-Ning Wong , Yoo-Joung Ko , Srikala S. Sridhar , Matt D. Galsky , Daniel Peter Petrylak , Tomasz M. Beer , Walter Michael Stadler , Peter H. O'Donnell , Cora N. Sternberg , Jonathan E. Rosenberg , Joaquim Bellmunt Molins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Bladder Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4522)
DOI
10.1200/jco.2012.30.15_suppl.4522
Abstract #
4522
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Clinical outcomes of patients with recurrent small cell lung cancer receiving third-line chemotherapy.
First Author: Koichi Saruwatari
Poster
2023 ASCO Annual Meeting
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
First Author: Romain Cohen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer
Poster
2022 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
First Author: Begoña Pérez-Valderrama